Skip to main content

Table 1 Demographics and indications for treatment

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

 

Thalidomide (N = 67)

Bevacizumab (N = 69)

N

%

N

%

Gender (% male)

41

61.2

23

33.3

Pathogenic gene

ENG (HHT1)

17

25.4

10

14.5

ACVRL1 (HHT2)

34

50.7

57

82.6

SMAD4 (JPHT)

2

3.0

1

1.4

 Not known

14

20.9

1

1.4

Treatment indication

 Epistaxis

48

71.6

14

20.3

 GI bleeding

11

16.4

8

11.6

 Epistaxis and GI bleeding

8

11.9

10

14.5

 High output cardiac failure

0

0

37

53.6

  1. Legend: N number of cases treated, GI gastrointestinal